肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2023年CSCO《乳腺癌诊疗指南》更新要点解读

2023-06-20 中国人民解放军总医院第五医学中心肿瘤医学部 中国肿瘤外科杂志 发表于上海

乳腺癌

该文总结了2023版CSCO乳腺癌诊疗指南早期乳腺癌部分的更新要点，并进行了详细解读。

中文标题：

2023年CSCO《乳腺癌诊疗指南》更新要点解读

发布机构：

中国人民解放军总医院第五医学中心肿瘤医学部

发布日期：

2023-06-20

简要介绍：

2023版CSCO乳腺癌诊疗指南基于循证医学证据和领域专家共识，考虑到国情及诊疗产品的可及性，在乳腺癌分类分层治疗的指导原则下，对乳腺癌的全程规范化治疗指南进行了更新和修订。该文总结了2023版CSCO乳腺癌诊疗指南早期乳腺癌部分的更新要点，并进行了详细解读。
 

相关资料下载：
2023年CSCO《乳腺癌诊疗指南》更新要点解读.pdf
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2024-03-07 中和制药东哥 来自湖南省

    谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2023-11-13 ms8000000455478267 来自江苏省

    如何获得积分下载？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2023-11-12 ms6000001473620636 来自广西

    对临床工作有很大指导意义！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2023-09-22 ms8000001769177689

    非常有用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2023-08-15 1467790cm53暂无昵称 来自浙江省

    有用

    0

相关指南

美国国家综合癌症网络临床实践指南：乳腺癌更新解读(2023V4)

哈尔滨医科大学附属肿瘤医院 · 2023-06-20

乳腺癌新辅助治疗中外指南对比解读

厦门大学附属翔安医院 · 2023-06-20

第三届关于乳房恶性潜在性不明的病变(B3病变)的国际共识会议

欧洲乳腺癌专科学会(EUSOMA,European Society of Breast Cancer Specialists) · 2023-06-17

2023 ASCO/CAP指南：人表皮生长因子受体2检测在乳腺癌中的应用（更新版）

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2023-06-07

2023 ESMO共识声明：HER2低表达乳腺癌的定义，诊断和管理

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2023-06-01

乳腺癌患者芳香化酶抑制剂诱导的骨关节症状预防和管理的证据总结

复旦大学护理学院 · 2023-04-10

拓展阅读

Radiology：动态增强MRI在极高密度乳腺女性患者中预测乳腺癌的发生

乳腺钼靶所得的乳腺FGT百分比已用于对女性进行MRI分类。此外，背景实质增强(BPE)被发现是乳腺癌的独立危险因素，但受到观察者内部和观察者之间的变异性的影响。

‘四大顶刊’一周研究导读：基因编辑疗法治疗眼病，再获突破性进展；乳腺癌可少切除，还可降低水肿风险；尿液检测可准确诊断高级别前列腺癌，可减少约一半的不必要活检

科学的进步如同一个梯子，能够为你打开新的世界。

读书报告 | 损伤基质：多西他赛在休眠期乳腺癌逃逸中的作用

该研究探索了多西他赛化疗导致乳腺癌休眠逃逸的机制，发现多西他赛不仅会导致低增殖的癌细胞变得高度增殖，而且还会增加它们的侵袭性。

“最毒”茶克星，水平越高，结局越好；不用化疗，疗效不减… | 前沿进展

三阴性乳腺癌（TNBC）约占所有乳腺癌病例的15%~20%，这部分乳腺癌患者通常预后较差，超过50%的患者在确诊治疗后3~5年内就会出现复发。TNBC相关前沿进展给患者带来了新的治疗策略。

读书报告 | CURB研究： 标准系统治疗联合立体放射外科治疗寡进展性乳腺癌和NSCLC的II期随机对照临床研究

对局部消融在转移性疾病灶负荷有限（寡转移）的患者中治疗应用的兴趣日益浓厚。多项前瞻性随机临床试验表明，消融性放射治疗可以提高寡转移癌患者的无进展生存率和总生存率。

Int J Gen Med：中国乳腺癌妇女糖尿病和前驱糖尿病糖化血红蛋白诊断的最佳截断值

在中国无糖尿病史的乳腺癌妇女中，未确诊糖尿病的患病率很高。在中国乳腺癌女性中，HbA1c诊断糖尿病和前驱糖尿病的最佳临界值分别为6.0%和5.5%。

乳腺癌HER2检测指南(2009版)

中国肿瘤科相关专家小组（统称） · 2009-12-01

2010 乳腺癌骨转移和骨相关疾病临床诊疗专家共识（2010版）

乳腺癌骨转移和骨相关疾病临床诊疗专家组 · 2010-01-01

2010 SBI/ACR推荐建议：乳腺癌影像学筛查

乳腺影像学会(SBI,Society of Breast Imaging) · 2010-01-20

2010 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2010-02-01

2010 ASCO-CAP指南：乳腺癌患者雌激素和雄激素受体的免疫组化检测

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-04-19

2010 ASCO指南：激素受体阳性乳腺癌妇女的辅助内分泌治疗

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-07-12